Björnsson, Marcus
Acharya, Chayan
Strandgården, Kerstin
Tiberg, Fredrik
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
https://doi.org/10.1007/s40262-023-01288-6
Documents that mention this clinical trial
Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
https://doi.org/10.1007/s40262-023-01288-6
Documents that mention this clinical trial
Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
https://doi.org/10.1007/s40262-023-01288-6
Funding for this research was provided by:
Camurus AB
Article History
Accepted: 17 July 2023
First Online: 16 August 2023
Declarations
:
: This analysis was sponsored by Camurus AB. Support for third-party writing assistance for this article, provided by Lucy-Paige Willows, BSc, and Rachel Hutchinson, PhD, Costello Medical, UK, was funded by Camurus AB in accordance with Good Publication Practice (GPP3) guidelines (ExternalRef removed).
: MB: Current employee and stock owner of Pharmetheus AB. CA: Current employee of Pharmetheus AB. KS: Employee of Camurus AB at the time of the analysis. Currently a consultant in Pharmacokinetics and Pharmacometrics at PKadvisor AB. FT: Current employee and shareholder of Camurus AB.
: The authors will not make data collected for the study analysis available to others.
: Ethics approval and informed consent of each trial participant were obtained before trial inclusion, as detailed previously in the primary publications from the 4 clinical trials or within the appropriate records on the ISRCTN.com or ClinicalTrials.gov registries (registration numbers: ISRCTN41550730, ISRCTN24987553, NCT02611752 and NCT02710526). These 4 clinical trials, and the analysis detailed here, were conducted in accordance with Good Clinical Practice Guidelines and the ethical principles as laid down in the 1964 Declaration of Helsinki.
: Oral and written informed consent to participate was obtained from all trial participants before enrollment in the trials.
: All the results presented in this article are in aggregate form, and no personally-identifiable information was used for this analysis.
: Due to its proprietary nature, the authors will not make code available to others.
: Substantial contributions to analysis conception and design: MB, CA, KS, and FT; substantial contributions to analysis and interpretation of the data: MB, CA, KS, and FT; drafting the article or revising it critically for important intellectual content: MB, CA, KS, and FT; final approval of the version of the article to be published: MB, CA, KS, and FT.